Literature DB >> 10623693

Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment.

G E Kim1, J H Cho, W I Yang, E J Chung, C O Suh, K R Park, W P Hong, I Y Park, J S Hahn, J K Roh, B S Kim.   

Abstract

PURPOSE: To investigate the patterns of systemic failure and the clinical outcome in patients with angiocentric lymphoma of the head and neck who were treated with radiation alone, and to discuss the optimal mode of treatment for these patients. PATIENTS AND METHODS: We reviewed the records of 92 patients with stage I or II angiocentric lymphoma who were treated at Yonsei Cancer Center between 1976 and 1994. All patients were treated with involved-field irradiation. Radiation doses ranged from 40 to 60 Gy (median dose, 50.4 Gy). Treatment response, patterns of treatment failure including systemic failure, and clinical outcome after radiation treatment were analyzed.
RESULTS: The most frequently involved site was the nasal cavity, either alone or in conjunction with other sites. In 16 patients (17.4%), angiocentric lymphoma was accompanied by cervical lymphadenopathy. Disease was classified as stage I in 62 patients (67.4%) and stage II in 30 patients (32.6%). After completion of radiation treatment, 61 patients (66.3%) achieved a complete response and 16 (17.4%) a partial response. Half of the patients (50.0%) ultimately experienced local recurrence with or without other components of failure, whereas regional failure was relatively uncommon (10.9%). Systemic failure occurred in 25.0% of patients during follow-up. Six patients had histologic findings identical to those at the time of the original disease (group I), whereas four patients exhibited morphologic features of frank lymphomas (group II). The majority of patients with systemic relapse had the predilection sites for widespread extranodal involvement, such as the skin, brain, lung, gastrointestinal tract, or testes. In addition, seven patients died from various medical illnesses or immunologic disorders, including hemophagocytic syndrome and second primary cancers (group III). After a median follow-up of 56 months, the overall survival and disease-free survival rates for all patients were 40.1% and 37.8%, respectively. All patients except one with systemic failure died within 1 year.
CONCLUSION: Treatment with radiation alone had suboptimal results, partly because of the occurrence of a variety of systemic failure with diverse clinicopathologic features. Given the frequent occurrence of systemic failure after radiation treatment, we believe that the multimodality treatment approach containing more effective chemotherapeutic agents should be incorporated in the treatment of angiocentric lymphoma confined to the head and neck.

Entities:  

Mesh:

Year:  2000        PMID: 10623693     DOI: 10.1200/JCO.2000.18.1.54

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  54 in total

1.  Lymphopenia during routine follow-up may predict relapse in patients with extranodal NK/T cell lymphoma.

Authors:  Liang Wang; Jing-hua Wang; Zhi-jun Wu-Xiao; Zhong-jun Xia; Hui-qiang Huang; Yue Lu
Journal:  Tumour Biol       Date:  2014-10-31

Review 2.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

Review 3.  Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature.

Authors:  Neal Luther; Jeffrey P Greenfield; Amy Chadburn; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

4.  Single pleural relapse of a nasal-type extranodal natural killer/t-cell lymphoma: a case report.

Authors:  Keunmo Kim; Youngmin Oh; Sung-Nam Lim; Song-Yi Choi; Ok-Jun Lee; Kang-Hyeon Choe; Ki-Man Lee; Jin-Young An
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-04-25

5.  Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

Authors:  Hui-Hui Ma; Li-Ting Qian; Hai-Feng Pan; Lin Yang; Hong-Yan Zhang; Zhi-Hua Wang; Jun Ma; Yu-Fei Zhao; Jin Gao; Ai-Dong Wu
Journal:  Med Oncol       Date:  2009-08-15       Impact factor: 3.064

Review 6.  Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.

Authors:  Bradley M Haverkos; Zenggang Pan; Alejandro A Gru; Aharon G Freud; Rachel Rabinovitch; Meng Xu-Welliver; Brad Otto; Carlos Barrionuevo; Robert A Baiocchi; Rosemary Rochford; Pierluigi Porcu
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

7.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

Review 8.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

Review 9.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

10.  Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation.

Authors:  Yasuo Mori; Takatoshi Aoki; Katsuto Takenaka; Takuji Yamauchi; Asataro Yamamoto; Kenjiro Kamezaki; Hiromi Iwasaki; Naoki Harada; Toshihiro Miyamoto; Koji Nagafuji; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2009-12-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.